Revvity (RVTY) Q1 2026 earnings review
Excising the China Drag Ignites Pro Forma Growth
Revvity dropped a strategic bombshell alongside its Q1 earnings: the divestiture of its China Immunodiagnostics business. After spending all of 2025 fighting localized DRG (Diagnosis-Related Group) reimbursement pressures, management simply excised the tumor. The optical impact is massive. While reported organic growth was a pedestrian 3%, removing the China drag reveals a pro forma organic growth rate of 6%. Diagnostics, the segment most plagued by the China issues, saw its pro forma organic growth hit an impressive 9%. Despite the top-line relief, profitability took a scheduled hit. Adjusted operating margins compressed to 23.6% from 25.6% a year ago—a deceleration management telegraphed last quarter due to an extra operating week and delayed cost-saving programs. Full-year pro forma guidance of $5.20-$5.30 EPS establishes a clean, high-growth baseline for the optimized portfolio.
🐂 Bull Case
Selling the China Immunodiagnostics unit instantly transforms Revvity's growth profile. A business that was an unpredictable anchor in 2025 is gone, boosting core organic growth to 6% and removing significant geopolitical and localized policy risks.
Stripped of the China drag, the Diagnostics segment delivered 9% pro forma organic growth. This proves the core underlying business (including Reproductive Health) is highly robust.
🐻 Bear Case
Adjusted operating margins fell 200 basis points YoY to 23.6%. This places immense pressure on the remaining quarters of FY26 to ramp margins back up to the targeted 28% run rate.
The divestiture is slightly dilutive to current earnings. Q1 Adjusted EPS was $1.06 on a reported basis, but only $1.04 pro forma. Management is trading current cash flow for top-line optics.
⚖️ Verdict: 🟢
Bullish. Trading $0.02 of quarterly EPS for a clean 6% organic growth profile is a brilliant strategic move. It dramatically simplifies the equity story and highlights the strength of the remaining Life Sciences and Diagnostics segments.
Key Themes
Strategic Divestiture Unlocks Core Diagnostics
The decision to sell the China Immunodiagnostics business is the defining event of the quarter. In 2025, this segment (roughly 6% of company revenue) suffered severe volume declines due to Chinese hospital reimbursement (DRG) changes. By eliminating it, total company pro forma organic growth doubled from 3% to 6%. More importantly, the Diagnostics segment's organic growth accelerated from 4% reported to an outstanding 9% pro forma.
Negative Operating Leverage Contradicts 'Execution' Claim
CEO Prahlad Singh cited 'strong execution' in the press release, but the segment data contradicts this. In the Life Sciences segment, revenue grew by $21.5M (+6% YoY), but Adjusted Operating Income actually fell by $1.7M, causing segment margins to collapse from 31.1% to 28.7%. True 'strong execution' should yield positive operating leverage on higher volumes. This reversing margin trend requires immediate scrutiny.
AI Innovation: Signals Synthetica Momentum
Revvity continues to transition from a pure hardware/reagents company into a SaaS-enabled workflow provider. The 'Signals Synthetica' AI-as-a-service platform integrates machine learning directly into preclinical R&D workflows. Validated by tier-one partnerships (like Eli Lilly in late 2025), this software franchise acts as a high-margin growth catalyst that insulates Revvity from capital equipment cyclicality.
Macro Picture: Preclinical End Markets Remain Fluid
While Pro Forma growth looks fantastic, Life Sciences organic growth remains stuck at 3%. The broader macro backdrop for academic and preclinical biotech funding remains cautious. Management has structured FY26 guidance without assuming a material recovery in instrument spending, meaning any prolonged macro deterioration could still threaten the newly optimized baseline.
Heavy Non-GAAP Adjustments Persist
The bridge between GAAP and Adjusted metrics remains a cavern. Q1 GAAP operating income was just $76M, compared to $168M adjusted. A massive $85M in intangible amortization and $10.6M in restructuring costs bridge the gap. While normal for a serial acquirer, investors must monitor these perpetual 'one-time' cash and non-cash adjustments that obscure true baseline profitability.
Other KPIs
Stable. Operating cash flow from continuing operations was $125.9M, offset by $19.8M in capital expenditures. This yields ~$106M in free cash flow, representing strong conversion on GAAP net income of $40.7M and supporting ongoing capital returns.
Decelerating sequentially but stable YoY. Down from the aggressive $168M pace set in 25Q4, but significantly higher than early 2024 levels. Revvity is utilizing its $1 billion authorization to organically boost EPS while its M&A pipeline remains disciplined.
Guidance
Stable. Excluding the China business, this implies 3% to 4% pro forma organic revenue growth. It indicates management is relying on current market conditions persisting, without baking in a sudden spike in biotech or academic capital equipment demand.
Accelerating. The midpoint of $5.25 represents roughly a 4% increase over FY25's reported $5.06, but it is being achieved on a smaller, optimized revenue base. It implies heavy margin expansion in the back half of the year since Q1 pro forma EPS started at just $1.04 (roughly 20% of the annual target).
Key Questions
Divestiture Proceeds and Capital Allocation
The pro forma balance sheet notes potential consideration of $140 million for the China Immunodiagnostics business. Will these proceeds be funneled directly into the $1 billion share repurchase authorization, or are you prioritizing bolt-on software M&A?
Margin Ramp Cadence
With Q1 pro forma adjusted operating margins at 24.0%, hitting your full-year targets requires a massive acceleration in H2. How much of this ramp is dependent on volume leverage versus the strict execution of internal cost-saving programs?
Life Sciences Operating Leverage
Life Sciences grew revenues by over $20 million year-over-year, yet operating profit declined in the segment. Can you walk us through the specific mix dynamics or cost pressures that caused this negative operating leverage?